Actelion Ltd (ALIOF) 141.5160 $ALIOF Kite Pharma Narrows

New Post Public Reply Private Reply Replies (0) Message Board

May 18, 2015 at 10:52 AM

Actelion Ltd (ALIOF) 141.5160 $ALIOF

Kite Pharma Narrows Q1 Loss, Misses Estimates; Gives View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 31 mins ago
Kite Pharma (KITE) reported a first-quarter 2015 loss of 36 cents per share, substantially narrower than the year-ago loss of 46 cents.
KITE: 46.54 (-3.48), GILD: 110.47 (+1.17), AMGN: 161.55 (-0.81)

Amgen Announces Positive Results on Migraine Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 15, 3:30PM CDT
Amgen Inc. (AMGN) announced positive results from a phase II study on pipeline candidate, AMG 334, at the 17th Congress of the International Headache Society in Spain.
VRX: 227.16 (+2.53), GILD: 110.47 (+1.17), AMGN: 161.55 (-0.81)

Endo/BioDelivery Reveal Encouraging Data on Pain Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 15, 2:35PM CDT
Endo along with its partner BioDelivery Sciences presented encouraging pivotal data from two phase III studies on Belbuca at the American Pain Society's annual scientific meeting.
BDSI: 8.55 (-0.22), ENDP: 83.05 (-2.30), GILD: 110.47 (+1.17)

Corcept Therapeutics' Korlym Positive in Breast Cancer Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 15, 2:25PM CDT
Corcept Therapeutics Incorporated (CORT) announced results from a multicenter phase I/II dose escalation study on Korlym and chemotherapy drug Halaven at the ASCO.
VRX: 227.16 (+2.53), GILD: 110.47 (+1.17), CORT: 5.80 (+0.05)

Teva Presents Encouraging Data from Chronic Migraine Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 15, 1:50PM CDT
Teva (TEVA) presented encouraging results from a phase IIb chronic migraine study on TEV-48125.
GILD: 110.47 (+1.17), TEVA: 60.51 (+0.28), ACOR: 29.83 (-0.21)

Heron Therapeutics' HTX-019 Meeting with FDA Successful - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 15, 1:40PM CDT
Heron Therapeutics, Inc. (HRTX) proposal for the use of 505(b)(2) development pathway for HTX-019 for chemotherapy-induced nausea and vomiting accepted by the FDA.
VRX: 227.16 (+2.53), HRTX: 13.73 (-0.40), MRK: 60.32 (+0.09)

GlycoMimetics' Leukemia Drug Gets Orphan Status in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 15, 1:30PM CDT
GlycoMimetics, Inc. (GLYC) announced that its proprietary oncology candidate GMI-1271 received orphan drug status from the FDA for the treatment of acute myeloid leukemia.
VRX: 227.16 (+2.53), PFE: 33.96 (-0.03), GLYC: 8.59 (+0.15)

What's in Store for Evogene (EVGN) this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 15, 10:00AM CDT
Premium biotechnology company Evogene Ltd. (EVGN) is set to report first-quarter 2015 results on May 19, 2015, before the markets close.
EVGN: 10.11 (-0.04), MON: 120.47 (-0.35), SYT: 87.70 (-0.20)

Clovis Oncology (CLVS) Jumps: Stock Adds 16.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 15, 7:51AM CDT
Clovis Oncology, Inc. (CLVS) was a big mover last session, as its shares rose almost 17% on the day.
CLVS: 93.84 (+1.10)

Sanofi (SNY) Exercises Celiac Disease Program Option - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 14, 3:45PM CDT
Sanofi (SNY) exercised its option to develop an antigen-specific immunotherapy with Selecta Biosciences for celiac disease.
GILD: 110.47 (+1.17), ACOR: 29.83 (-0.21), SNY: 50.25 (-0.27)

Vertex Pharmaceuticals' Orkambi Wins FDA Panel Backing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 13, 11:40AM CDT
Vertex Pharmaceuticals' (VRTX) Orkambi is a step closer to U.S. approval with an FDA panel giving a favorable opinion for the treatment of cystic fibrosis (12 years of age and above) who have two copies of the F508del mutation.
VRTX: 126.07 (-0.14), GILD: 110.47 (+1.17), ATHX: 1.31 (+0.04)

Dr. Reddy's (RDY) Earnings and Revenues Rise in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 13, 9:00AM CDT
Dr. Reddy's Laboratories (RDY) reported fourth-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 49 cents, up 8.9% from the year-ago quarter.
SUPN: 13.15 (+0.02), RDY: 56.26 (+0.95)

McKesson Beats on Q4 Earnings & Revenues, Guides Strong - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 13, 8:20AM CDT
McKesson Corporation (MCK) reported fourth-quarter fiscal 2015 earnings of $2.94 per share, up from $2.71 in the year-ago quarter, which comfortably beat the Zacks Consensus Estimate of $2.75.
VRX: 227.16 (+2.53), MCK: 241.73 (+1.80), GILD: 110.47 (+1.17)

Further data on selexipag (Uptravi) and macitentan (Opsumit) to be presented at American Thoracic Society (ATS) Conference 2015
Thomson Reuters ONE - Wed May 13, 12:00AM CDT
Actelion Pharmaceuticals Ltd / Further data on selexipag (Uptravi) and macitentan (Opsumit) to be presented at American Thoracic Society (ATS) Conference 2015 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Johnson & Johnson's Invega Sustenna sNDA Suffers Setback - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 12, 4:05PM CDT
Johnson & Johnson (JNJ) suffered a setback when the FDA issued a complete response letter (CRL) in response to the company's sNDA for Invega .
JNJ: 103.17 (+0.87), VRX: 227.16 (+2.53), GILD: 110.47 (+1.17)

Eli Lilly & BioNTech Collaborate for Cancer Immunotherapies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 12, 4:00PM CDT
Eli Lilly and Company (LLY) and BioNTech AG announced that they have signed a research collaboration agreement for the discovery of novel cancer immunotherapies.
VRX: 227.16 (+2.53), ANAC: 62.17 (-0.20), LLY: 72.90 (unch)

Fluidigm Q1 Revenues Lower than Expected, Stock Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 12, 3:55PM CDT
Shares of Fluidigm Corporation (FLDM) fell over 26% after it announced disappointing first quarter 2015 financial results on May 7.
GILD: 110.47 (+1.17), FLDM: 25.65 (+0.62), CYTX: 0.70 (+0.04)

Juno Therapeutics (JUNO) Q1 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 12, 3:44PM CDT
Juno Therapeutics (JUNO) reported a first-quarter 2015 loss of 32 cents per share (including stock-based compensation expense), narrower than the Zacks Consensus Estimate of a loss of 35 cents.
FATE: 6.89 (+0.09), AZN: 68.77 (-0.52), JUNO: 41.03 (-2.34)

Ligand Pharmaceuticals Tops Q1 Earnings, Affirms View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 12, 3:41PM CDT
Ligand Pharmaceuticals (LGND) reported first-quarter 2015 earnings of 20 cents per share, significantly higher than the Zacks Consensus Estimate of 12 cents.
AMGN: 161.55 (-0.81), LGND: 86.65 (+2.44), NVS: 104.23 (+0.48)

Pfizer Acquires Stake in Dutch Biopharmaceutical Company - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 12, 3:20PM CDT
Pfizer Inc. (PFE) announced that it has acquired a minority equity interest in a privately-held Dutch biopharmaceutical company AM-Pharma B.V.
VRX: 227.16 (+2.53), PFE: 33.96 (-0.03), HSP: 88.19 (+0.09)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Political Jitters Push US Investors to Golden Visas

Judging by the latest buzz from La Vida's 2026 survey, the golden ticket for many US investors isn't a hot stock but something far more unexpected: the coveted 'Golden Visa.' Out of over 5,000 wealthy individuals invited to participate, 94.3% are mulling over a second residency or citizenship, and the big trigger? Political concerns. It's a clear sign that plenty of...

CMS Energy's Q3 Marks Change: Restructuring Boost

A Tale of Two Earnings Few things get my blood pumping like a new quarter's earnings dance, and CMS Energy (NYSE:CMS) is stealing the show right now with its two-faced Q3 results. Digging deep into the numbers, we see this Michigan-based energy player reporting a gauntlet of figures that have investors raising their eyebrows. On one hand, reported GAAP earnings dropped to...

Biddance AI Posts H1 Loss Despite Revenue Gains

A Hard Look at the Numbers for Biddance AI Diving into Biddance AI Systems' first half of 2026 financial results, you can't ignore the taste of both progress and predicament. The revenue leapt to $1.23 million from $0.74 million year-on-year, a decent hike, sure, but let's not pop the champagne just yet. The net loss ballooned too, hitting $1.37 million compared to last...

Northern.tech Enhances Product Software Control & Security

The Evolution of Product Software Management Over in Palo Alto, Northern.tech has just flipped the switch on something pretty significant—component orchestration in their Mender solution. This isn't just your run-of-the-mill software update. They're talking about managing software across the entire system of a connected product. You know, pulling all the strings at...

Ukraine's Satellite: A New Era of Sovereignty

Ukraine's Bold Satellite Leap Alright, folks! Ukraine’s got a satellite cruising in orbit, and let me tell you, this ain't just some vanity space flight—it’s a downright pivotal shift in their communications game. Been a rough road to this milestone, but now we're seeing them break free from relying on foreign infrastructure for their satellite needs. What this...

Shaking Up Loyalty: TrueLoyal's Bold Move You know, in an era when brands are trying everything to keep customers from jumping ship, getting someone like Erica Thompson on board is like snagging a golden ticket. TrueLoyal just announced they’ve tapped into a veteran, a real heavy-hitter in the loyalty game, to head their loyalty strategy, customer retention, and...

Diplomats Immerse in Xi'an's Rich History and Culture

Embarking on Shaanxi's Cultural Odyssey You think you've seen culture until you get a whiff of Shaanxi’s rich tapestry. From October 9 to 12, diplomats from Belarus, Morocco, Albania, and six other nations took a deep dive into China’s vibrant history and arts at the 'Discover China Cultural Tour.' Forget the usual conference room drudgery—this was all about getting...

Encompass Health Eyes Houston Growth with New Hospital

Fort Bend County: The Next Step in Encompass Health's Journey Kicking off with some Texas flair, Encompass Health is making notable moves in Fort Bend County, venturing to boost its presence in the greater Houston area. It's no surprise given that this neck of the woods is seeing quite the growth spurt lately. Encompass Health, no stranger to living large, is charting new...

Teamsters Secure Strong Contract for CA Waste Workers

Teamsters Flex Muscles in So-Cal Sanitation Sector So here's one for the books: 700 Waste Management workers represented by Teamsters Local 396 just locked down a fresh collective bargaining agreement in Los Angeles and Orange counties. And let me tell you, this isn’t just another contract—it's a testament to what solidarity can wring out of a massive corporation. The...

Centerspace Sale Faces Scrutiny Amid Investor Concerns

Potential Undervaluation Looms Large over Centerspace Sale On a crisp October day, the saga of Centerspace's proposed sale to Independence Realty Trust (NYSE: IRT) is stirring the pot. Charles C. Foti, Jr., Esq., and the law firm Kahn Swick & Foti, LLC are throwing a wrench into the works, questioning the soundness of the whole shebang. The deal, valued at 3.800 shares of...